Triptorelin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IM Prostate cancer As 3 mth depot: 11.25 mg 12 wkly. Endometriosis; Uterine fibroids 3 or 3.75 mg 4 wkly for up to 6 mth. Begin during the 1st 5 days of the menstrual cycle. SC Female infertility W/ gonadotrophins, 0.1 mg/day starting from 2nd day of the menstrual cycle for 10-12 days.
Dosage Details
Intramuscular
Endometriosis, Uterine fibroids
Adult: 3 or 3.75 mg by IM Inj every 4 wk for up to 6 mth. Begin treatment during the 1st 5 days of the menstrual cycle.

Parenteral
Precocious puberty
Child: 50 mcg/kg, using the 3 mg depot preparation by IM Inj every 4 wk. Alternatively, using the 3.75 mg depot preparation, <20 kg 1.875 mg, 20-30 kg 2.5 mg, >30 kg 3.75 mg by IM or SC inj; first 3 doses to be given at 14 day intervals with further doses given every 4 wk.

Parenteral
Prostate cancer
Adult: 3 or 3.75 mg by IM Inj every 4 wk using 1 mth depot preparation. The 1st dose may be preceded with 0.1 mg daily for 7 days by SC inj. Alternatively, 11.25 mg IM every 12 wk using the 3 mth depot formulation.

Subcutaneous
Female infertility
Adult: In conjunction with gonadotrophins, 0.1 mg daily by SC Inj starting from the 2nd day of the menstrual cycle for 10-12 days.
Contraindications
Hypersensitivity to triptorelin and other luteinising hormone-releasing hormone (LHRH) or LHRH agonists; as sole treatment in prostate cancer patients with spinal cord compression or evidence of spinal metastases; progressive brain tumours in children. Pregnancy; lactation.
Special Precautions
Patients with pituitary adenoma; weight-related amenorrhoea until weight corrected; polycystic ovary disease or endometriotic cysts; metabolic bone disease. Monitor closely as there may be initial worsening of signs and symptoms during first few wk of therapy. Contraceptive measures to be taken to protect against unwanted ovulation in females.
Adverse Reactions
Hot flushes, weight gain, sleep disturbances, headache, hypertension, weight gain, decreased libido, abnormal vision, mood disorders, nausea, abdominal pain or discomfort, rash and impotence. Transient pain, redness or local inflammation at the inj site may occur. Prostate cancer: During first few wk, bone pain, worsening of urinary obstruction symptoms and/or worsening of neurological signs of vertebral metastases (back pain, weakness or paresthesia of the lower limbs). Gynaecomastia, vertigo and dizziness. Endometriosis: Initial worsening of pelvic pain, dysmenorrhoea with heavy menstrual bleeding or spotting. Sweating, vaginal dryness, dyspareunia, breast pain, hair loss, small loss in bone density. Precocious puberty: Mild or moderate withdrawal bleeding in the first mth of treatment.
Potentially Fatal: Anaphylactic shock.
IM/Parenteral/SC: X
Drug Interactions
Decrease in LHRH receptors in pituitary with hyperprolactinaemic drugs antagonises effects of triptorelin.
Lab Interference
Suppression of pituitary-gonadal axis may lead to misleading results of pituitary-gonadal function tests if conducted during treatment and after cessation of therapy.
Action
Description: Triptorelin is a synthetic analogue of natural gonadotropin-releasing hormone. Initial admin stimulates the release of pituitary gonadotrophins with a transient increase in testosterone levels in men and in oestradiol levels in women, leading to an initial worsening of symptoms during the first wk. Prolonged admin leads to a suppression of gonadotrophins and a decrease in plasma testosterone or oestradiol after approximately 20 days, which is maintained for as long as triptorelin is admin.
Pharmacokinetics:
Absorption: Rapidly absorbed with peak plasma concentrations after 40 minutes (subcutaneous inj).
Excretion: Half life: 7.5 hr.
Disclaimer: This information is independently developed by MIMS based on Triptorelin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Decapeptyl CR
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in